Publications, Pharmaceutical

Using pharmacokinetics to confirm bioequivalence in fluticasone DPIs

Streamlining the complexities of confirming the bioequivalence of generic orally inhaled drug products by would be helpful in reducing the costs of widely used respiratory therapeutics.

This paper describes pharmacokinetic studies of three fluticasone propionate dry powder inhaler formulations with respect to their effectiveness in detecting differences in regional deposition. The formulations were chosen for their ability to deliver deposition in different areas of the lung while at the same time ensuring a comparable overall dose. Systemic pharmacokinetics were assessed in a randomized, double-blind, four-way, crossover study, with 24 healthy volunteers. The results support the use of pharmacokinetic studies to provide relevant data for the assessment of pulmonary performance via parameters such as regional deposition, available dose, and residence time.

Download Publication
6 Feb 2021

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

12 Jul 2022

Digital Health and Digital Therapeutics: Where are we heading and...

Webinars, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation

Read More
12 Jul 2022

How pMDIs are transforming Asthma and COPD treatments

Publications, Pharmaceutical, Sustainability, Device Innovations, Market Insights, Product Solutions

Read More
5 Jul 2022

Drug, Device, Digital: Reimagined Healthcare

Webinars, Pharmaceutical, Innovation & Insights, Brand Differentiation, Market Insights, Product Solutions

Read More
30 Jun 2022

Supporting Patients and HCPs with New Digital Technology

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
1 2 3 14
Back To Top